| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;106:927.)
© 2002 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Division of Pharmacology, University of Antwerp, Wilrijk, Belgium (W.M., G.R.Y.D.M., A.G.H., M.M.K.); HistoGeneX, Edegem, Belgium (M.W.M.K.); and the Cardiovascular Translational Research Institute Middelheim Antwerp (CATRIMA), Antwerp, Belgium (M.M.K.).
Correspondence to Dr Mark M. Kockx, Department of Pathology, AZ Middelheim, Lindendreef 1, B-2020 Antwerp, Belgium. E-mail mark.kockx{at}uia.ua.ac.be
| Abstract |
|---|
|
|
|---|
Methods and Results We observed increased immunoreactivity against the oxidative DNA damage marker 7,8-dihydro-8-oxo-2'-deoxyguanosine (8-oxo-dG) in plaques of the carotid artery compared with the adjacent inner media and nonatherosclerotic mammary arteries. Strong 8-oxo-dG immunoreactivity was found in all cell types of the plaque including macrophages, smooth muscle cells, and endothelial cells. As shown by competitive ELISA, carotid plaques contained 160±29 8-oxo-dG residues/105 dG versus 3±1 8-oxo-dG residues/105 dG in mammary arteries. Single-cell gel electrophoresis showed elevated levels of DNA strand breaks in the plaque. The overall number of apoptotic nuclei was low (1% to 2%) and did not correlate with the amount of 8-oxo-dG immunoreactive cells (>90%). This suggests that initial damage to DNA occurs at a sublethal level. Several DNA repair systems that are involved in base excision repair (redox factor/AP endonuclease [Ref 1] and poly(ADP-ribose) polymerase 1 [PARP-1]) or nonspecific repair pathways (p53, DNA-dependent protein kinase) were upregulated, as shown by Western blotting and immunohistochemistry. Overexpression of DNA repair enzymes was associated with elevated levels of proliferating cell nuclear antigen.
Conclusions Our findings provide evidence that oxidative DNA damage and repair increase significantly in human atherosclerotic plaques.
Key Words: atherosclerosis oxidative stress apoptosis
| Introduction |
|---|
|
|
|---|
| Methods |
|---|
|
|
|---|
|
Antibodies
The following mouse monoclonal antibodies were used: anti-PARP-1 (clone C2-10; PharMingen), anti-7,8-dihydro-8-oxo-2'-deoxyguanosine (clone N45.1; Japan Institute for the Control of Aging), anti-p53 (clone DO-7), anti-CD68 (clone PG-M1), anti-proliferating cell nuclear antigen (PCNA; clone PC10; DAKO), anti-phospho-p53 (S392; clone SP2/0; Novocastra), anti-DNA-PK (clone 42-psc), anti-DNA polymerase ß (clone 18S; Neomarkers), and anti-ß-actin (clone AC-15), anti-smooth muscle cell actin (clone 1A4), and anti-SC-35 (clone SC-35; Sigma).
Polyclonal rabbit antibodies included anti-hNTH1, anti-MTH1, and anti-hOgg1 from Novus Biologicals; anti-phospho-p53 (S15; New England Biolabs); anti-active caspase-3 (PharMingen); anti-inducible nitric oxide synthase (BIOMOL); anti-nitrotyrosine (Upstate Biotechnology); and anti-Ref-1 (C-20; Santa Cruz Biotechnology). Goat anti-mouse and sheep anti-rabbit peroxidase-conjugated secondary antibodies were purchased from Jackson and DAKO, respectively.
Immunohistochemistry and DNA In Situ End Labeling
The immunohistochemical reactions were performed by an indirect peroxidase antibody conjugate method.12 For the detection of oligonucleosomal DNA cleavage, a stringent terminal deoxynucleotidyl transferase end-labeling (TUNEL) technique was used.13 TUNEL staining was combined with an immunohistochemical stain for SC-35 to avoid aspecific labeling.13
Protein Isolation and Immunoblot Assays
Four human carotid endarterectomy specimens and 4 control samples were pooled to reduce specimen-to-specimen variation and were subsequently homogenized.10 Immunoblot assays were performed as previously described.10
Quantitative Measurement of 7,8-Dihydro-8-Oxo-2'-Deoxyguanosine
Genomic DNA was extracted from mammary arteries (n=5) and carotid endarterectomy specimens (n=5) using the Wizard Genomic DNA Purification Kit (Promega). DNA was digested with nuclease P1, phosphodiesterase I, and alkaline phosphatase to yield free deoxynucleosides.14 To determine the amount of deoxyguanosine (dG), hydrolyzed samples and dG standards were introduced onto a Prodigy ODS(3) HPLC column (150x1.0 mm). Deoxyguanosine was detected at 254 nm (Waters CapLC system). The amount of 7,8-dihydro-8-oxo-2'-deoxyguanosine (8-oxo-dG) was measured by using competitive ELISA (Highly Sensitive 8-OHdG ELISA Kit, Japan Institute for the Control of Aging). Finally, the ratio of 8-oxo-dG/105 dG was calculated.
Alkaline Single-Cell Gel Electrophoresis Assay
The alkaline comet assay or single-cell gel electrophoresis assay was performed as described.10 Peripheral blood monocytes were used as negative controls.
Statistical Analysis
Age, total, and LDL cholesterol, as well as comet assay parameters and 8-oxo-dG values were compared with the unpaired Students t test. Other patient characteristics were evaluated by the Fishers exact test. A value of P<0.05 was considered significant.
| Results |
|---|
|
|
|---|
-Smooth muscle cell actin immunoreactive cells were nearly absent in these regions (<0.2% of the total area). Some foam cells surrounding the necrotic core were strongly immunoreactive against inducible nitric oxide synthase (Figure 1A). Nitrotyrosine was also detected in this region (Figure 1B). Insoluble multilaminated material composed of oxidized lipids and proteins was present in the cytoplasm of many macrophages. We found some larger extracellular lipid deposits in the necrotic core.
|
Oxidative DNA Modifications
Smooth muscle cells (SMCs) of mammary arteries showed weak immunoreactivity for the oxidative DNA damage marker 8-oxo-dG. In contrast, strong 8-oxo-dG immunoreactivity was found in all cell types of the plaque (>90% of the total area), including macrophages, SMCs, and endothelial cells (Figures 2A and 2D). 8-oxo-dG immunoreactivity was localized predominantly in the nucleus of the labeled cells. Adjacent fragments of the inner media stained minimally or did not stain at all. Plaque cells showed an
55-fold higher level of 8-oxo-dG in comparison with mammary arteries (160±29 versus 3±1 8-oxo-dG residues/105 dG; Figure 3). The majority of 8-oxo-dG immunoreactive cells in the plaque (>95%) showed immunoreactivity for splicing factor SC-35 but were negative for active caspase-3 (Figure 1C) and were not labeled by the TUNEL technique (Figure 1D). Immunoreactivity for 8-oxo-dG did not differ in intimal xanthomata from thin fibrous cap atheromata (data not shown).
|
|
DNA Strand Breaks
Alkaline single cell gel electrophoresis revealed that the number of DNA strand breaks was significantly higher in cells of the carotid endarterectomy specimens compared with cells derived from mammary arteries (Figures 4A and 4B). Most cells in the plaque (>90%) contained DNA strand breaks with varying outcomes (Figures 4A and 4B). However, only a minority of cells (1% to 2%) showed TUNEL reactivity. Cells containing a massive amount of DNA strand breaks were localized predominantly in regions of the plaque that contained large amounts of oxidized lipid deposits (Figure 4E). In mammary arteries (Figures 4A and 4C) and peripheral blood monocytes (Figure 4D), DNA strand breaks were scarce or completely absent.
|
Expression of DNA Repair Enzymes
Several proteins involved in DNA repair were upregulated in plaques of carotid endarterectomy specimens when compared with nonatherosclerotic vessels. Western blots revealed an increased expression of p53, p53 phosphorylated at Ser15 and Ser392, DNA-PK, redox factor/AP endonuclease Ref-1, and PARP-1, but a constitutive expression of DNA polymerase ß, the N-glycosylases hOgg1 and hNTH1, and 8-oxoGTPase (MTH1; Figure 5). Western blots were confirmed by immunohistochemistry. Strong nuclear immunoreactivity for Ref-1 and DNA-PK was present in the entire plaque (>90% of the total area) in both macrophages and SMCs (Figures 2B, 2C, 2E, and 2F). The carotid artery endothelium and endothelial cells from microvessels were negative for Ref-1 and DNA-PK or showed occasional staining. SMCs from the media adjacent to the plaque and from mammary arteries stained minimally. In contrast with Ref-1 and DNA-PK immunolabeling, only a subpopulation of cells in the plaque stained for p53, phospho-p53, or PARP-1 (Figures 6A and 6B). Upregulation of p53 and PARP-1 occurred predominantly in the macrophage population of the plaque but was undetectable in the adjacent media and mammary arteries. Overexpression of DNA repair enzymes was associated with elevated levels of PCNA (Figure 6C).
|
|
Immunoreactivity for Ref-1 and DNA-PK did not differ in intimal xanthomata from thin fibrous cap atheromata. However, overexpression of PARP-1, p53, and PCNA was found predominantly in macrophages around the necrotic core of thin fibrous cap atheromata (Figure 6).
| Discussion |
|---|
|
|
|---|
A · T transversion mutations in repair-deficient cells.4 Previous reports showed an increased mutation rate and widespread microsatellite instability in human atherosclerotic lesions.16,17 These may be related to the accumulation of oxidized base residues. In addition, ROS may also generate DNA strand interruptions.3 Single-cell gel electrophoresis revealed that the number of DNA strand breaks was raised significantly in the plaque compared with nonatherosclerotic vessels. Because DNA strand breaks are fragile sites, they can attract undesirable recombination events. Elevated levels of DNA strand breaks in the plaque may therefore account for the chromosomal rearrangements described previously.18 It is important to note that extensive chromosome abnormalities in SMCs can be associated with transformation events (eg, intimal uterine leiomyosarcomas).19 Atherosclerotic plaques contain a large monoclonal population of SMCs20,21 and thus may be regarded as monoclonal neoplasms of the arterial wall. This is consistent with the findings that DNA extracted from atherosclerotic plaques had a transforming ability when transfected into NIH3T3 cells22 and that SMCs cultured from plaque tissue retained transforming potential throughout many cell passages.23 Monoclonality of plaque SMCs could be caused by the expansion of a large, preexisting patch of SMCs.20,21 An alternative mechanism for monoclonality that corresponds with increased levels of oxidative DNA damage is the creation of a new lineage of SMCs. This may occur either through genetic mutation or through epigenetic changes. If true, somatic mutations of SMCs may play an important role in the pathogenesis of atherosclerotic plaques.
Severe oxidative DNA damage can induce apoptosis by activating a variety of proapoptotic proteins. In the present study, atherosclerotic plaques were characterized by the appearance of apoptotic cell death, but the overall number of TUNEL-positive nuclei was low (1% to 2%) and did not correlate with the amount of 8-oxo-dG immunoreactive cells (>90%). Therefore, we assume that cells in the plaque contain a sublethal level of oxidative DNA modifications and/or strand breaks and thus do not undergo the execution phase of apoptosis. On the contrary, most cells surrounding the necrotic core are labeled for splicing factor SC-35, suggesting that these cells are viable and metabolically active. However, we cannot rule out the possibility that DNA lesions accumulate with time and eventually induce plaque cells to undergo apoptotic cell death.24
DNA damage cannot be tolerated in mammals if left unrepaired. Therefore, cells have developed many defense systems to remove DNA damage. A major repair mechanism for oxidative DNA damage, including 8-oxo-dG and DNA strand breaks, is the base excision repair pathway.25,26 In the present study, Western blot analyses and immunohistochemical stains indicated that there are several DNA repair enzymes that are upregulated in the plaque, either those involved in base excision repair (Ref-1, PARP-1) or in nonspecific repair pathways (p53, DNA-PK). Furthermore, we demonstrated that plaque p53 contains at least 2 phosphorylated residues, Ser15 and Ser392, which stabilize and activate the protein in the plaque. Activation of p53 by phosphorylation is an important regulatory event in the arterial vessel wall because p53 deficiency, specifically in macrophages, leads to a significant doubling of atherosclerotic lesion size.27 Overexpression of some base excision repair enzymes does not always lead to increased protection against DNA-damaging agents.26 For this reason, it remains to be determined whether the capacity of the vascular cells to repair endogenous lesions after upregulation of specific repair enzymatic activity is increased. A nonphysiological level of certain repair proteins may even prove detrimental to mammalian cells.26 This is particularly clear for PARP-1, whose imbalanced production leads to necrotic cell death as a result of NAD+ and ATP depletion.28 In this case, PARP-1 overexpression may also contribute to the formation of a necrotic core, which is the hallmark of an atherosclerotic lesion.
Immunohistochemical analysis revealed the abundant expression of both DNA-PK and Ref-1 in the entire plaque. DNA-PK is a serine/threonine kinase that serves as an essential upstream activator of p53.29 Nevertheless, the significance of the upregulation of Ref-1 in atherosclerotic plaques is unclear and remains to be elucidated. Herring et al30 could not demonstrate increased resistance to DNA damage in cells overexpressing Ref-1, indicating that increased levels of Ref-1 cannot improve the repair efficiency. It is important to note that Ref-1 is also a redox factor and, thus, a widespread regulator of transcription factors that control multiple events in the life cycle of various cell types. Downregulation of Ref-1 expression after induction of hypoxia into endothelial cells precedes DNA fragmentation and apoptotic cell death. This suggests that Ref-1 is a crucial enzyme that determines cell fate.31
Overexpression of DNA repair enzymes was associated with elevated levels of PCNA. Because this protein is essential for DNA replication, many groups have used it as an important marker for cell proliferation. However, recent evidence suggests additional roles for PCNA in chromatin assembly, RNA transcription, and DNA repair.32 We assumed that high levels of oxidative stress in the plaque could trigger a unconventional repair pathway that modulates PCNA expression, given that mammalian cell extracts can repair oxidative DNA modifications by an alternative PCNA-dependent base excision repair pathway.33 Similar conclusions were reported for macrophages treated with oxidized LDL,34 as well as for cardiac myocytes in dilated cardiomyopathy.35
In summary, our findings show that oxidative DNA damage and repair increase significantly in human atherosclerotic plaques. There is currently a lack of essential information regarding the functional consequences of damaged DNA in human plaques, besides the potential role in carcinogenesis and cell death. Of particular interest, however, is the finding that several factors associated with the presence of DNA adducts in aorta SMCs (ie, age, smoking habits, blood lipids, and blood pressure) are also known to play a major role in atherogenesis.7 In this context, detection of DNA damage may provide a useful biomarker not only in carcinogenesis but also in atherogenesis.
| Acknowledgments |
|---|
Received March 28, 2002; revision received May 31, 2002; accepted May 31, 2002.
| References |
|---|
|
|
|---|
B-independent and -dependent pathways. Circ Res. 2001; 88: 12471253.This article has been cited by other articles:
![]() |
T. Thum and J. Borlak LOX-1 Receptor Blockade Abrogates oxLDL-induced Oxidative DNA Damage and Prevents Activation of the Transcriptional Repressor Oct-1 in Human Coronary Arterial Endothelium J. Biol. Chem., July 11, 2008; 283(28): 19456 - 19464. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Allard, N. Figg, M. R. Bennett, and T. D. Littlewood Akt Regulates the Survival of Vascular Smooth Muscle Cells via Inhibition of FoxO3a and GSK3 J. Biol. Chem., July 11, 2008; 283(28): 19739 - 19747. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Pacher and C. Szabo Role of the Peroxynitrite-Poly(ADP-Ribose) Polymerase Pathway in Human Disease Am. J. Pathol., July 1, 2008; 173(1): 2 - 13. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-Q. Lai, K. L. Tucker, L. D. Parnell, X. Adiconis, B. Garcia-Bailo, J. Griffith, M. Meydani, and J. M. Ordovas PPARGC1A Variation Associated With DNA Damage, Diabetes, and Cardiovascular Diseases: The Boston Puerto Rican Health Study Diabetes, April 1, 2008; 57(4): 809 - 816. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. von Lukowicz, P. O. Hassa, C. Lohmann, J. Boren, V. Braunersreuther, F. Mach, B. Odermatt, M. Gersbach, G. G. Camici, B. E. Stahli, et al. PARP1 is required for adhesion molecule expression in atherogenesis Cardiovasc Res, April 1, 2008; 78(1): 158 - 166. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Mowbray, D.-H. Kang, S. G. Rhee, S. W. Kang, and H. Jo Laminar Shear Stress Up-regulates Peroxiredoxins (PRX) in Endothelial Cells: PRX 1 AS A MECHANOSENSITIVE ANTIOXIDANT J. Biol. Chem., January 18, 2008; 283(3): 1622 - 1627. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Oumouna-Benachour, C. P. Hans, Y. Suzuki, A. Naura, R. Datta, S. Belmadani, K. Fallon, C. Woods, and A. H. Boulares Poly(ADP-Ribose) Polymerase Inhibition Reduces Atherosclerotic Plaque Size and Promotes Factors of Plaque Stability in Apolipoprotein E-Deficient Mice: Effects on Macrophage Recruitment, Nuclear Factor-{kappa}B Nuclear Translocation, and Foam Cell Death Circulation, May 8, 2007; 115(18): 2442 - 2450. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liu, R. Prasad, W. A. Beard, P. S. Kedar, E. W. Hou, D. D. Shock, and S. H. Wilson Coordination of Steps in Single-nucleotide Base Excision Repair Mediated by Apurinic/Apyrimidinic Endonuclease 1 and DNA Polymerase beta J. Biol. Chem., May 4, 2007; 282(18): 13532 - 13541. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Qu, G.-H. Liu, B. Huang, and C. Chen Nitric oxide controls nuclear export of APE1/Ref-1 through S-nitrosation of Cysteines 93 and 310 Nucleic Acids Res., April 3, 2007; 35(8): 2522 - 2532. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mahmoudi, J. Mercer, and M. Bennett DNA damage and repair in atherosclerosis Cardiovasc Res, July 15, 2006; 71(2): 259 - 268. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Zschenker, T. Illies, and D. Ameis Overexpression of lysosomal Acid lipase and other proteins in atherosclerosis. J. Biochem., July 1, 2006; 140(1): 23 - 38. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Sokhansanj and D. M. Wilson III Estimating the effect of human base excision repair protein variants on the repair of oxidative DNA base damage. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 1000 - 1008. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Takeshita, J. Byun, T. Q. Nhan, D. K. Pritchard, S. Pennathur, S. M. Schwartz, A. Chait, and J. W. Heinecke Myeloperoxidase Generates 5-Chlorouracil in Human Atherosclerotic Tissue: A POTENTIAL PATHWAY FOR SOMATIC MUTAGENESIS BY MACROPHAGES J. Biol. Chem., February 10, 2006; 281(6): 3096 - 3104. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Kim, S. J. Son, E. K. Kim, S. N. Kim, D. G. Yoo, H. S. Kim, S. W. Ryoo, S. D. Lee, K. Irani, and B. H. Jeon Apurinic/apyrimidinic endonuclease1/redox factor-1 inhibits monocyte adhesion in endothelial cells Cardiovasc Res, February 1, 2006; 69(2): 520 - 526. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Forlenza and G. E. Miller Increased Serum Levels of 8-Hydroxy-2'-Deoxyguanosine in Clinical Depression Psychosom Med, January 1, 2006; 68(1): 1 - 7. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Fragedaki, M. Nebel, N. Schupp, K. Sebekova, W. Volkel, A. Klassen, M. Pischetsrieder, M. Frischmann, T. Niwa, J. Vienken, et al. Genomic damage and circulating AGE levels in patients undergoing daily versus standard haemodialysis Nephrol. Dial. Transplant., September 1, 2005; 20(9): 1936 - 1943. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Schrijvers, G. R.Y. De Meyer, M. M. Kockx, A. G. Herman, and W. Martinet Phagocytosis of Apoptotic Cells by Macrophages Is Impaired in Atherosclerosis Arterioscler. Thromb. Vasc. Biol., June 1, 2005; 25(6): 1256 - 1261. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Patterson Blood Pressure Control Goes Nuclear Circ. Res., October 29, 2004; 95(9): 849 - 851. [Full Text] [PDF] |
||||
![]() |
B. H. Jeon, G. Gupta, Y. C. Park, B. Qi, A. Haile, F. A. Khanday, Y.-X. Liu, J.-M. Kim, M. Ozaki, A. R. White, et al. Apurinic/Apyrmidinic Endonuclease 1 Regulates Endothelial NO Production and Vascular Tone Circ. Res., October 29, 2004; 95(9): 902 - 910. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Zhang, J. Yang, and L. K. Jennings Attenuation of neointima formation through the inhibition of DNA repair enzyme PARP-1 in balloon-injured rat carotid artery Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H659 - H666. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M Wasserman and J. N Topper Adaptation of the endothelium to fluid flow: in vitro analyses of gene expression and in vivo implications Vascular Medicine, February 1, 2004; 9(1): 35 - 45. [Abstract] [PDF] |
||||
![]() |
D. M. J. Curfs, E. Lutgens, M. J. J. Gijbels, M. M. Kockx, M. J. A. P. Daemen, and F. J. van Schooten Chronic Exposure to the Carcinogenic Compound Benzo[a]Pyrene Induces Larger and Phenotypically Different Atherosclerotic Plaques in ApoE-Knockout Mice Am. J. Pathol., January 1, 2004; 164(1): 101 - 108. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Pierce, J. Whitlark, and L. Dory Extracellular Superoxide Dismutase Polymorphism in Mice Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1820 - 1825. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. COOKE, M. D. EVANS, M. DIZDAROGLU, and J. LUNEC Oxidative DNA damage: mechanisms, mutation, and disease FASEB J, July 1, 2003; 17(10): 1195 - 1214. [Abstract] [Full Text] [PDF] |
||||